Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment
Titel:
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment
Auteur:
Efstathiou, E. Bozas, G. Kostakopoulos, A. Kastritis, E. Deliveliotis, C. Antoniou, N. Skarlos, D. Papadimitriou, C. Dimopoulos, M.A. Bamias, A.